Lassmann Michael, Nosske Dietmar, Reiners Christoph
Department of Nuclear Medicine, University of Würzburg, 97080 Würzburg, Germany.
Radiat Environ Biophys. 2002 Sep;41(3):173-8. doi: 10.1007/s00411-002-0164-5. Epub 2002 Sep 7.
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease which reduces the quality of life and leads to disability in approximately one-third of the patients. The spectrum of therapeutic modalities is limited. The renaissance of the use of (224)Ra-radium chloride for AS treatment, however, gives rise to concern which should result in the reconsideration of (224)Ra dosimetry and in the discussion of the risks associated with this treatment. The present study introduces new dosimetric calculations for alpha and beta/gamma rays performed according to the model proposed by the International Commission on Radiological Protection (ICRP). After a treatment schedule of 10 intravenous injections, each with 1 MBq of (224)Ra, the absorbed doses were calculated to be highest on the bone surface of the patient (4.4 Gy) with a resulting effective dose of 2.5 Sv.
强直性脊柱炎（AS）是一种慢性炎症性风湿性疾病，会降低生活质量，并导致约三分之一的患者残疾。治疗方式的范围有限。然而，使用（224）氯化镭治疗AS的复兴引发了关注，这应该促使人们重新考虑（224）镭剂量测定，并讨论这种治疗相关的风险。本研究根据国际放射防护委员会（ICRP）提出的模型，介绍了针对α射线和β/γ射线的新剂量计算方法。在进行10次静脉注射的治疗方案后，每次注射1 MBq的（224）镭，计算得出患者骨表面的吸收剂量最高（4.4 Gy），有效剂量为2.5 Sv。
